Morgane C. Mouslim, DVM, ScM

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.

Real-world cross-validation of insurer and hospital price transparency data finds low overlap but high concordance between data sources.

This study leverages newly available hospital pricing data to explore hospital-insurer contracts from a large hospital chain.

Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.